Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Commentary on: "Dirty-appearing white matter in multiple sclerosis: preliminary observations of myelin phospholipid and axonal loss", by G. R. W. Moore, et al. in J Neurol (2008) 255: DOI 10.1007/s00415-008-0002-z.
Tablet-based screening improves continence management in multiple sclerosis.
Voiding Dysfunction in Multiple Sclerosis.
Structural Brain Network Characteristics Can Differentiate CIS from Early RRMS.
The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis.
[Semaphorin 4 in multiple sclerosis].
Predictors of successful acceptance of home telemanagement in veterans with Multiple Sclerosis.
Myelin Proteolipid Protein Complexes with αv Integrin and AMPA Receptors In Vivo and Regulates AMPA-Dependent Oligodendrocyte Progenitor Cell Migration through the Modulation of Cell-Surface GluR2 Expression.
Multiple sclerosis: Fatigue-a warning sign for multiple sclerosis?
Inequalities In Access to Treatment for Multiple Sclerosis In England Continue Despite Service Improvement Initiatives And Policy Reforms.
Progression in disability and regional grey matter atrophy in relapsing-remitting multiple sclerosis.
Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study.
Uric acid: a potential biomarker of multiple sclerosis and of its disability.
Reduced serum vitamin D levels in neuromyelitis optica.
Myelin basic protein induces neuron-specific toxicity by directly damaging the neuronal plasma membrane.
Comparison of the affective symptomatology between liver transplant recipients and patients with multiple sclerosis considering their functional impairment.
A 3meter Timed Tandem Walk is an early marker of motor and cerebellar impairment in fully ambulatory MS patients.
High-Throughput Screening Platform for the Discovery of New Immunomodulator Molecules from Natural Product Extract Libraries.
Erratum to: Disentangling Multiple Sclerosis and depression: an adjusted depression screening score for patient-centered care.
Mesenchymal stem cells (MSC) derived from mice with experimental autoimmune encephalomyelitis (EAE) suppress EAE and have similar biological properties with MSC from healthy donors.
Plasmapheresis and immunoadsorption in patients with steroid refractory multiple sclerosis relapses.
Changes in the expression of the glutamate transporter EAAT3/EAAC1 in health and disease.
Is serum vitamin D levels associated with disability in patients with newly diagnosed multiple sclerosis?
Inflammatory Mechanisms and Oxidative Stress as Key Factors Responsible for Progression of Neurodegeneration: Role of Brain Innate Immune System.
Upper Limb Rehabilitation in People With Multiple Sclerosis: A Systematic Review.
Pages
« first
‹ previous
…
599
600
601
602
603
604
605
606
607
…
next ›
last »